JAGX

Jaguar Health Inc

34.46

Sep 22 • 3:59 PM ET +31.79 (1,190.64%)

42.34

Aftermarket • 5:23 PM ET +7.88 (22.87%)

Healthcare Biotechnology USA Nano NASD

Today, 9:10 AMJaguar Health announces that its Napo unit and the company have received FDA user-fee waivers for fiscal 2027 for Mytesi and Canalevia-CA1

Peers: APRE GOVX KAPA KPRX LNAI BCDA BIVI NEUP CALC CVM

Scroll to Statements

Index	-
Market Cap	11.87M
Enterprise Value	21.89M
Income	-52.42M
Sales	27.82M
Book/sh	20.43
Cash/sh	19.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	47
IPO	May 13, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	0.43
P/B	1.69
P/C	1.80
P/FCF	-
EV/EBITDA	-
EV/Sales	0.79
Quick Ratio	0.40
Current Ratio	0.69
Debt/Eq	2.76
LT Debt/Eq	0.39
Option/Short	No / No

EPS (ttm)	-5482.20
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	92.49% 85.33%
Sales past 3/5Y	-1.26% 4.17%
EPS Y/Y TTM	85.50%
Sales Y/Y TTM	135.52%
EPS Q/Q	95.63%
Sales Q/Q	-58.88%
Earnings	Aug 19 BMO
EPS/Sales Surpr.	- -

Insider Own	1.35%
Insider Trans	0.00%
Inst Own	0.10%
Inst Trans	-
ROA	-88.27%
ROE	-498.47%
ROIC	-395.01%
Gross Margin	75.00%
Oper. Margin	-90.22%
Profit Margin	-188.46%
SMA20	279.99%
SMA50	160.35%
SMA200	-82.76%
Trades

Shs Outstand	0.34M
Shs Float	0.34M
Short Float	4.75%
Short Ratio	0.56
Short Interest	0.02M
52W High	1280.95 -97.31%
52W Low	2.35 1366.38%
Volatility	38.36% 20.69%
ATR (14)	4.13
RSI (14)	81.10
Beta	-0.16
Rel Volume	919.18
Avg Volume	29.04K
Volume	26,688,323

Perf Week	922.86%
Perf Month	164.82%
Perf Quarter	-10.26%
Perf Half Y	-83.56%
Perf YTD	-92.95%
Perf Year	-96.77%
Perf 3Y	-99.98%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	3937.50
Prev Close	2.67
Price	34.46
Change %	1190.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight	$5
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$2

Today 09:05AM	Jaguar Health Receives Fee Waivers from FDA (ACCESSWIRE) +1,190.64%
Sep-15-26 09:00AM	Jaguar Health, Inc. Announces Reverse Stock Split (ACCESSWIRE) -29.57%
Sep-10-26 09:00AM	All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) (ACCESSWIRE) -12.91%
Sep-08-26 11:06AM	Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise (InvestorsHub) -30.60%
09:00AM	Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs (ACCESSWIRE)
08:30AM	Loading…
Sep-04-26 08:30AM	Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) (ACCESSWIRE) -14.06%
Aug-26-26 09:00AM	Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs (ACCESSWIRE)
Aug-20-26 01:02AM	Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ... (GuruFocus.com) -5.50%
Aug-19-26 04:00PM	Jaguar Health Reports Second Quarter 2026 Financials (ACCESSWIRE) -5.35%
Aug-18-26 09:00AM	Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates (ACCESSWIRE) +11.10%
Aug-05-26 09:00AM	Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 (ACCESSWIRE) +5.50%
Jul-28-26 09:00AM	Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog (ACCESSWIRE)
Jul-22-26 09:00AM	Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) (ACCESSWIRE) +5.56%
Jun-30-26 09:00AM	Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) (ACCESSWIRE)
Jun-25-26 09:00AM	Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend (ACCESSWIRE)
09:00AM	Loading…
Jun-23-26 09:00AM	Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Jun-22-26 09:00AM	Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program (ACCESSWIRE) +16.00%
Jun-18-26 09:01AM	Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health (TMX Newsfile) -5.46%
09:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention (ACCESSWIRE)
Jun-12-26 09:00AM	Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases (ACCESSWIRE)
Jun-08-26 04:15PM	Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders (ACCESSWIRE)
May-28-26 10:00AM	Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders (ACCESSWIRE)
May-27-26 09:00AM	Jaguar Health Compliant with Nasdaq Bid Price Rule (ACCESSWIRE)
May-26-26 05:00PM	Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +6.87%
May-20-26 04:40PM	Jaguar Health Reports First Quarter 2026 Financials (ACCESSWIRE) +9.39% -5.45%
09:00AM	Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference (ACCESSWIRE)
May-19-26 09:00AM	Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer (ACCESSWIRE) -9.32%
May-08-26 09:00AM	Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule (ACCESSWIRE)
May-06-26 09:00AM	Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) (ACCESSWIRE) -6.31%
May-04-26 08:30AM	Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health (ACCESSWIRE) -51.42%
08:30AM	Loading…
Apr-29-26 08:30AM	Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs (ACCESSWIRE) -6.64%
Apr-27-26 09:00AM	Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split (ACCESSWIRE) -27.77%
Apr-24-26 08:30AM	Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) (ACCESSWIRE)
Apr-20-26 04:15PM	Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders (ACCESSWIRE)
Apr-13-26 08:30AM	Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs (ACCESSWIRE) +5.69%
Apr-11-26 03:00AM	Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Apr-08-26 08:30AM	Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Apr-07-26 08:30AM	Jaguar Health Reports 2025 Financials (ACCESSWIRE)
Apr-02-26 09:00AM	Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress (ACCESSWIRE)
Mar-18-26 09:00AM	FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) (ACCESSWIRE) -8.04%
Mar-16-26 09:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression (ACCESSWIRE)
Mar-11-26 09:00AM	Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts (ACCESSWIRE) +19.99%
Mar-09-26 09:00AM	Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants (ACCESSWIRE) -16.85%
Mar-03-26 09:00AM	Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 (ACCESSWIRE) -23.21%
Feb-18-26 09:00AM	Jaguar Health Announces a Special One-time Stock Dividend (ACCESSWIRE)
Jan-22-26 09:00AM	Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi (ACCESSWIRE) -9.78%
Jan-16-26 01:54PM	The Surge In Jaguar Health Stock: What's Happening Now? (Benzinga) +87.05%
Jan-14-26 09:00AM	Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts (ACCESSWIRE) +10.61%
Jan-12-26 09:00AM	Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million (ACCESSWIRE) -20.95%
Jan-06-26 09:00AM	Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication (ACCESSWIRE) +9.71%
Jan-02-26 09:00AM	Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE) +7.12%
Dec-15-25 09:00AM	Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (ACCESSWIRE) -11.85%
Dec-10-25 09:00AM	FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE) +13.68%
Dec-08-25 04:15PM	Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders (ACCESSWIRE) +6.36%
Dec-02-25 09:00AM	Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study (ACCESSWIRE)
Nov-24-25 09:00AM	Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones (ACCESSWIRE)
Nov-20-25 09:00AM	In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial (ACCESSWIRE) -8.15%
Nov-17-25 04:00PM	Jaguar Health Inc (JAGX) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Ongoing Challenges (GuruFocus.com) -8.03%
08:00AM	Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue (ACCESSWIRE)
Nov-14-25 09:00AM	Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates (ACCESSWIRE)
Nov-13-25 09:00AM	Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting (ACCESSWIRE)
Oct-24-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) +5.53%
Oct-06-25 09:00AM	Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
Sep-30-25 09:00AM	FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease (ACCESSWIRE) +10.43%
Sep-25-25 09:00AM	Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Sep-24-25 09:00AM	Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition (ACCESSWIRE) +6.97%
Sep-23-25 09:00AM	Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE)
Sep-21-25 09:10AM	Jaguar Health Completes Private Placement Deal (Insider Monkey)
Sep-05-25 09:00AM	Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE) +7.27%
Aug-21-25 09:00AM	Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Aug-19-25 04:15PM	Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders (ACCESSWIRE) -7.25%
09:00AM	Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
Aug-14-25 08:00AM	Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue (ACCESSWIRE) -20.08%
Aug-12-25 09:00AM	Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates (ACCESSWIRE) +8.29%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jul-10-25 08:30AM	Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs (ACCESSWIRE)
Jul-08-25 09:00AM	Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca (ACCESSWIRE)
Jun-30-25 09:00AM	Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient (ACCESSWIRE)
Jun-26-25 09:15AM	Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs (TipRanks) -7.19%
09:00AM	Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset (ACCESSWIRE)
Jun-25-25 09:00AM	Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Jun-24-25 04:15PM	Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 (ACCESSWIRE) +12.96%
Jun-23-25 09:00AM	Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer (ACCESSWIRE)
Jun-17-25 09:00AM	Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE) -6.23%
07:00AM	Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream (GlobeNewswire)
Jun-11-25 10:00AM	First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs (ACCESSWIRE)
Jun-09-25 09:00AM	Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer (ACCESSWIRE) -6.40%
Jun-06-25 09:00AM	Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series (ACCESSWIRE)
May-21-25 08:00AM	Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -27.05%
May-20-25 09:15AM	First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
May-16-25 07:09AM	Q1 2025 Jaguar Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.91%
03:12AM	Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... (GuruFocus.com)
May-15-25 02:30PM	Jaguar Health Reports First Quarter 2025 Financials (ACCESSWIRE) -10.86%
May-14-25 09:00AM	Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates (ACCESSWIRE) -6.52%
May-08-25 09:30AM	Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs (ACCESSWIRE) -20.95%
May-07-25 09:15AM	Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts (ACCESSWIRE)
Apr-30-25 08:15AM	Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients (ACCESSWIRE)
Apr-28-25 08:15AM	Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast (ACCESSWIRE)
Apr-17-25 09:00AM	Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress (ACCESSWIRE)
Apr-16-25 09:50AM	Jaguar Health to present results from OnTarget study in breast cancer patients (TipRanks) +9.81%

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

FounderMs. Lisa A. Conte

Chief Scientific Officer & Chair of Scientific Advisory BoardDr. Pravin R. Chaturvedi Ph.D.

J.D.Mr. Jonathan S. Wolin CPA

Chief of Sustainable SupplyDr. Steven R. King Ph.D.

CFO & TreasurerMs. Carol R. Lizak M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JAGX

Jaguar Health Inc

Upgrade your Finviz experience